Synthetic opDNA® utilised in Phase I/II US clinical trials

Summary by AI BETAClose X

4basebio PLC announced that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II US clinical trials with an mRNA product developed using 4basebio’s proprietary opDNA® template, following FDA Investigational New Drug (IND) approval. The supply agreement with the partner was signed in April 2024. This milestone follows 4basebio receiving GMP certification from the UK’s MHRA in April 2025 for its late-phase manufacturing facility. The opDNA® template supports mRNA invitro transcription (IVT) processes, offering cost, purity and timeline advantages over traditional plasmid DNA.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings